Dipexium Pharmaceuticals (NASDAQ: PLXP) and ZIOPHARM Oncology (NASDAQ:ZIOP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, analyst recommendations and institutional ownership.
Insider & Institutional Ownership
19.7% of Dipexium Pharmaceuticals shares are held by institutional investors. Comparatively, 41.9% of ZIOPHARM Oncology shares are held by institutional investors. 47.7% of Dipexium Pharmaceuticals shares are held by company insiders. Comparatively, 10.4% of ZIOPHARM Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a summary of recent ratings and recommmendations for Dipexium Pharmaceuticals and ZIOPHARM Oncology, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ZIOPHARM Oncology has a consensus price target of $16.50, indicating a potential upside of 188.97%. Given ZIOPHARM Oncology’s stronger consensus rating and higher possible upside, analysts plainly believe ZIOPHARM Oncology is more favorable than Dipexium Pharmaceuticals.
Earnings & Valuation
This table compares Dipexium Pharmaceuticals and ZIOPHARM Oncology’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Dipexium Pharmaceuticals||$375,950.00||202.21||-$8.09 million||N/A||N/A|
|ZIOPHARM Oncology||$6.39 million||125.67||-$48.70 million||($0.50)||-11.42|
Dipexium Pharmaceuticals has higher revenue, but lower earnings than ZIOPHARM Oncology.
This table compares Dipexium Pharmaceuticals and ZIOPHARM Oncology’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Dipexium Pharmaceuticals has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500. Comparatively, ZIOPHARM Oncology has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500.
ZIOPHARM Oncology beats Dipexium Pharmaceuticals on 7 of the 12 factors compared between the two stocks.
About Dipexium Pharmaceuticals
PLx Pharma Inc., formerly Dipexium Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen. PLxGuard delivery system uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs to selectively release these drugs to targeted portions of the GI tract. The Company’s lead product Aspertec 325 mg is a liquid-fill aspirin capsule for prevention of cardiovascular disease. Through PLxGuard delivery system the Company creates a lipid-based formulation of ibuprofen, PL1200 Ibuprofen Capsules, 200 mg.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.
Receive News & Ratings for Dipexium Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dipexium Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.